FREE TREATMENT REPORT
See ratings and reviews when you sign up for an account.
Nasonex? Nasal Suspension 50 ?g Long-term Designated Drug Use Investigation
This study is currently Recruiting
October 2011 By Schering-Plough
First Recieved on May 14, 2009
Last Updated on October 31, 2011
The investigation will be conducted to define safety and efficacy under the conditions of
post-marketing use of this drug in subjects with allergic rhinitis.
Post-marketing surveys are not considered applicable clinical trials and thus the results of
this survey will not be posted at its conclusion. The results will be submitted to public
health officials as required by applicable national and international laws.
||Observational Model: Cohort, Time Perspective: Prospective
Resources/Links provided by NLM:
|Study Start Date:
|Estimated Primary Completion Date:
Patients with perennial allergic rhinitis
Patients with seasonal allergic rhinitis (including patients who also have perennial allergic rhinitis)
Metered-dose spray type suspension containing 50 ?g mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 ?g) Duration: up to 6 months
|Ages Eligible for Study:||N/A|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||No|
- Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis.
- Patients with an infection for which there is no effective antimicrobial drug or
systemic fungal infection [symptoms may exacerbate]
- Patients with a history of hypersensitivity to any ingredient of this drug
- Coordinating Location